Skip to main content

Advertisement

SpringerLink
Log in

A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib

  • Clinical Trial Report
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

It is widely known that ROS1 rearrangement mostly occurs in the adenocarcinoma subtype of non-small-cell lung cancer. Patients with squamous cell carcinoma harboring ROS1 rearrangement are extremely rare. This is a case report of a squamous cell carcinoma patient with ROS1 rearrangement. An 84-year-old Chinese woman with a about 6.6 cm mass in the right middle lobe and right pleural effusion, enlarged mediastinal and hilar lymph nodes was diagnosed with stage IIIB lung squamous cell carcinoma harboring ROS1 rearrangement is highly sensitive to crizotinib in the first treatment setting. This is the first time to report lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. We hope that oncologists will notice this phenomenon and it will help the lung squamous cell carcinoma patient to get longer overall survival time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

ROS1:

c-ros oncogene 1

NSCLC:

Non-small-cell lung cancer

ORR:

Objective response rate

DoR:

Duration of response

EGFR:

Epidermal growth factor receptor

KRAS:

Kirsten rat sarcoma viral oncogene homolog

BRAF:

v-Raf murine sarcoma viral oncogene homolog B

References

  1. Bergethon K, Shaw AT, Ou SH et al (2012) ROS1rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863–870

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Go H, Kim DW, Kim D et al (2013) Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 8(11):1445–1450

    Article  PubMed  CAS  Google Scholar 

  3. Zhao W, Choi YL, Song JY et al (2016) ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer 94:22–27

    Article  PubMed  Google Scholar 

  4. Wang R, Zhang Y, Pan Y et al (2015) Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 6(33):34300–34308

    PubMed  PubMed Central  Google Scholar 

  5. Matsumura Y, Umemura S, Ishii G et al (2015) Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma. J Cancer Res Clin Oncol 141(12):2159–2170

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Penault-Llorca F, Tixier L, Perrot L, Cayre A (2016) Strategy for molecular testing in pulmonary carcinoma. Ann Pathol 36(1):73–79

    Article  PubMed  Google Scholar 

  7. Schwab R, Petak I, Kollar M et al (2014) Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1):109–111

    Article  PubMed  Google Scholar 

  8. Kenmotsu H, Serizawa M, Koh Y et al (2014) Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays. BMC Cancer 14:786

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Mazières J, Zalcman G, Crinò L et al (2015) Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33:992–999

    Article  PubMed  CAS  Google Scholar 

  10. Moro-Sibilot D, Faivre L, Zalcman G et al (2015) Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial. J Clin Oncol 33:8065a

    Google Scholar 

  11. Pfizer Inc. (2014) EU Xalkori (crizotinib) summary of product characteristics. http://www.ema.europa.eu/docs/enGB/document library/EPAR-ProductInformation/human/002489/WC500134759.pdf. Accessed 23 Apr 2014

  12. Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394 (and supplemental material)

    Article  PubMed  CAS  Google Scholar 

  13. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011–1019

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Kim D-W, Ahn M-J, Shi Y et al (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Poster presented at the 48th annual meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, June 1–5

Download references

Acknowledgements

The authors would like to thank Dr. Rongzheng Ren for editing the manuscript.

Funding

National Natural Science Foundation of China (81207106). Science and Technology Commission of Shanghai Municipality (17401932400).

Author information

Authors and Affiliations

  1. Department of Integrative Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zheng Min Road, Shanghai, 200433, People’s Republic of China

    Lixia Ju, Mingquan Han & Jinmei Su

  2. Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

    Chunyan Wu & Zhengwei Dong

Authors
  1. Lixia Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingquan Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jinmei Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chunyan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhengwei Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lixia Ju.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient in this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ju, L., Han, M., Su, J. et al. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib. Cancer Chemother Pharmacol 82, 561–564 (2018). https://doi.org/10.1007/s00280-018-3660-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3660-2

Keywords

Search

Navigation